- By ICR Secretariat
- Posted Tuesday, November 29, 2022
Infex begins study of pseudomonas aeruginosa candidate RESP-X
Phase 1 research will evaluate tolerability and safety of therapy among healthy volunteers
Infex – a company focusing on anti-infectives specialist – has announced that the first patients have been dosed in its phase 1 study researching candidate RESP-X.